Respiratory infection complicating HIV infection

Current Opinion in Infectious Diseases

Volumn 21, Issue 2, 2008, Pages 184-190

  Davis, J Lucian ^a,b,c   Fei, Matthew ^a,b   Huang, Laurence ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Bacterial pneumonia; Critical care; HIV AIDS; Pneumocystis (carinii) jirovecii pneumonia; Tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; CYTOKINE; EFAVIRENZ; GAMMA INTERFERON; INFLUENZA VACCINE; ISONIAZID; PNEUMOCOCCUS VACCINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; TUBERCULOSTATIC AGENT;

ANTIBIOTIC PROPHYLAXIS; BACTERIAL PNEUMONIA; CLINICAL TRIAL; CYTOKINE RELEASE; DEVELOPING COUNTRY; DIAGNOSTIC PROCEDURE; DRUG SENSITIVITY; FUNGAL COLONIZATION; HOSPITAL CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE FUNCTION TEST; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; INFECTION CONTROL; INFECTION PREVENTION; INFLUENZA; INTENSIVE CARE; LIVER TOXICITY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NEUROTOXICITY; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; PREVALENCE; RESPIRATORY TRACT INFECTION; REVIEW; RISK REDUCTION; T CELL BASED INTERFERON GAMMA RELEASE ASSAY; T LYMPHOCYTE; TREATMENT OUTCOME; TUBERCULOSIS; UNITED STATES; VIRUS INFECTION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-INFECTIVE AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, MULTIPLE; HUMANS; PNEUMONIA, BACTERIAL; RESPIRATORY TRACT INFECTIONS; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 43149092078     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/QCO.0b013e3282f54fff     Document Type: Review

References (35)

1. Kohli R, Lo Y, Homel P, et al. Bacterial pneumonia, HIV therapy, and disease progression among HIV-infected women in the HIV epidemiologic research (HER) study. Clin Infect Dis 2006; 43:90-98. The rate of bacterial pneumonia in HIV-infected women remains extremely high despite the introduction of ART.
2. Centers for Disease Control and Prevention: Guidelines for preventing opportunistic infections among HIV-infected persons: 2002 Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep 2002, 51:1-52.
3. + count less than 200 cells/μl.
4. Flannery B, Heffernan RT, Harrison LH, et al. Changes in invasive pneumococcal disease among HIV-infected adults living in the era of childhood pneumococcal immunization. Ann Intern Med 2006; 144:1-9. This cohort study suggested that the introduction of the pediatric pneumococcal conjugate vaccine has decreased the rate of invasive pneumococcal disease in HIV-infected adults.
5. Klein MB, Lu Y, DelBalso L, et al. Influenzavirus infection is a primary cause of febrile respiratory illness in HIV-infected adults, despite vaccination. Clin Infect Dis 2007; 45:234-240. Influenza is a common cause of febrile respiratory symptoms in HIV-infected patients receiving ART and presenting to an outpatient clinic for care despite high rates of prior influenza vaccination.
6. Getahun H, Harrington M, O'Brien R, et al. Diagnosis of smear-negative pulmonary tuberculosis in people with HIV infection or AIDS in resourceconstrained settings: informing urgent policy changes. Lancet 2007; 369:2042-2049. This paper presents a compelling argument for modification of national tuberculosis evaluation algorithms in HIV-infected patients.
7. Dowdy DW, Chaisson RE, Moulton LH, et al. The potential impact of enhanced diagnostic techniques for tuberculosis driven by HIV: a mathematical model. AIDS 2006; 20:751-762. A sophisticated mathematical analysis of the impact of a variety of diagnostic and public health measures on tuberculosis-control in areas of high HIV prevalence is presented.
8. Mazurek GH, Jereb J, Lobue P, et al. Guidelines for using the QuantiFERONTB Gold test for detecting Mycobacterium tuberculosis infection, United States. MMWR Recomm Rep 2005; 54:49-55.
9. Luetkemeyer AF, Charlebois ED, Flores LL, et al. Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals. Am J Respir Crit Care Med 2007; 175:737-742. The first large comparative study of TIGRA and TST performance in HIV-infected patients raises difficult questions about how to interpret discordant results between the two tests.
10. Jafari C, Ernst M, Kalsdorf B, et al. Rapid diagnosis of smear-negative tuberculosis by bronchoalveolar lavage enzyme-linked immunospot. Am J Respir Crit Care Med 2006; 174:1048-1054.
11. Wood R, Middelkoop K, Myer L, et al. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med 2007; 175:87-93.
12. Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21:1441-1448. In spite of its retrospective design, this study provides a thought-provoking examination of the efficacy of IPT in HIV-infected patients.
13. Elzi L, Schlegel M, Weber R, et al. Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin Infect Dis 2007; 44:94-102.
14. Cohen T, Lipsitch M, Walensky RP, et al. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci U S A 2006; 103:7042-7047. This paper presents an important discussion of the pros and cons of IPT for latent tuberculosis infection in HIV-infected persons.
15. Gandhi NR, Moll A, Sturm AW, et al. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 2006; 368:1575-1580. All HIV and tuberculosis specialists should be familiar with the specter of highly transmissable XDR tuberculosis described in this article, which may serve as a sentinel warning of a new and enormous challenge for tuberculosis control.
16. Moore DA, Evans CA, Gilman RH, et al. Microscopic-observation drug-susceptibility assay for the diagnosis of TB. N Engl J Med 2006; 355: 1539-1550. The MODS assay is a landmark development in the quest for tuberculosis diagnostics for the developing world.
17. Nahid P, Gonzalez LC, Rudoy I, et al. Treatment outcomes of patients with HIV and tuberculosis. Am J Respir Crit Care Med 2007; 175:1199-1206. In an era in which treatment shortening is in vogue, this paper explores the possibility that a different approach may be necessary in HIV-infected patients.
18. Friedland G, Khoo S, Jack C, et al. Administration of efavirenz (600 mg/day) with rifampicin results in highly variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV. J Antimicrob Chemother 2006; 58:1299-1302.
19. Breen RA, Miller RF, Gorsuch T, et al. Virological response to highly active antiretroviral therapy is unaffected by antituberculosis therapy. J Infect Dis 2006; 193:1437-1440.
20. Schiffer JT, Sterling TR. Timing of antiretroviral therapy initiation in tuberculosis patients with AIDS: a decision analysis. J Acquir Immune Defic Syndr 2007; 44:229-234. In a hypothesis-generating study, the authors find that the consequences of delaying ART in HIV-tuberculosis co-infection may outweigh the benefits.
21. Bourgarit A, Carcelain G, Martinez V, et al. Explosion of tuberculin-specific Th1-responses induces immune restoration syndrome in tuberculosis and HIV co-infected patients. AIDS 2006; 20:F1-F7.
22. Lawn SD, Myer L, Bekker LG, et al. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21:335-341. A postulated mechanism for IRIS raises the question, can a diagnostic test for IRIS be far behind?
23. Friedland G, Churchyard GJ, Nardell E. Tuberculosis and HIV coinfection: current state of knowledge and research priorities. J Infect Dis 2007; 196 (Suppl 1):S1-S3. The conveners of an expert symposium on HIV-tuberculosis co-infection introduce an excellent supplemental issue to the Journal of Infectious Diseases, which provides current overviews of the most important issues in the field.
24. Huang L, Morris A, Limper AH, et al. An Official ATS Workshop Summary: Recent advances and future directions in pneumocystis pneumonia (PCP). Proc Am Thorac Soc 2006; 3:655-664. This is a concise overview of recent advances in PCP.
25. Aderaye G, Bruchfeld J, Aseffa G, et al. Pneumocystis jirovecii pneumonia and other pulmonary infections in TB smear-negative HIV-positive patients with atypical chest X-ray in Ethiopia. Scand J Infect Dis 2007; 39:1045-1053. This report highlights the frequency of bacterial pneumonia and PCP in HIV-infected patients in Africa who are sputum smear negative for acid-fast bacilli.
26. Wong ML, Back P, Candy G, et al. Pneumocystis jirovecii pneumonia in African miners at autopsy. Int J Tuberc Lung Dis 2006; 10:756-760. This extremely comprehensive autopsy study of African miners documents a high rate of unsuspected PCP and presumably HIV before death.
27. + count remains under 200 cells/μl.
28. Huggett JF, Taylor MS, Kocjan G, et al. Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveolar lavage fluid of HIV-infected patients. Thorax 2007; 10 Aug [Epub ahead of print]. This paper describes a novel means of PCP diagnosis based on a PCR assay utilizing primers to the heat shock protein 70 gene.
29. Morris A, Kingsley LA, Groner G, et al. Prevalence and clinical predictors of Pneumocystis colonization among HIV-infected men. AIDS 2004; 18:793-798.
30. Morris A, Sciurba FC, Lebedeva IP, et al. Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization. Am J Respir Crit Care Med 2004; 170:408-413.
31. Norris KA, Morris A, Patil S, et al. Pneumocystis colonization, airway inflammation, and pulmonary function decline in acquired immunodeficiency syndrome. Immunol Res 2006; 36:175-187. This excellent review describes the association between Pneumocystis colonization and obstructive lung disease.
32. Morris A, Wachter RM, Luce J, et al. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 2003; 17:73-80.
33. Miller RF, Allen E, Copas A, et al. Improved survival for HIV infected patients with severe Pneumocystis jirovecii pneumonia is independent of highly active antiretroviral therapy. Thorax 2006; 61:716-721. This article shows that mortality from severe PCP requiring ICU care has decreased over time but is independent of ART, suggesting that other factors such as low tidal volume ventilation for acute respiratory distress syndrome and fluid conservative management may be responsible.
34. Morris A, Masur H, Huang L. Current issues in critical care of the human immunodeficiency virus-infected patient. Crit Care Med 2006; 34:42-49. This is an overview of the changing epidemiology of HIV-infected patients in the ICU during the ART era.
35. Huang L, Quartin A, Jones D, et al. Intensive care of patients with HIV infection. N Engl J Med 2006; 355:173-181. This review focuses on use of ART in the ICU. The article includes a useful clinical algorithm that provides a framework for making decisions regarding use of ART in the ICU.